← Home
🚀 Sign up Free for Company Insights & Valuation!
Sign up for free to get access to the best public company valuation and insights. Get started today and unlock the potential of your investments!
Sign up free
DiaSorin 
Healthcare & biotech / Biotechnology
At a Glance | Core Facts | Company Due Diligence | Industry Due Diligence | Competitors | Stock Swings | News | Income | Balance | Cash Flow | Growth | Enterprise | Ratios | Metrics | Dividends | Risks | SWOT | Porter's Five Forces | PEST | Score Positive | Clusters | Reports | WebOverview
DiaSorin is a global company that specializes in the development, production, and distribution of diagnostic tests for the clinical laboratory market. The company was founded in 1968 in Italy and has since expanded to have a presence in over 60 countries. DiaSorin is a leader in the field of immunodiagnostics and molecular diagnostics, with a focus on infectious diseases, autoimmune disorders, and other chronic conditions.
The company's headquarters are located in Saluggia, Italy, and it also has major operations in the United States, China, and other European countries. DiaSorin's products are used in hospitals, laboratories, and research institutions worldwide.
The company's product line includes over 40 diagnostic test systems that are used to detect various diseases and conditions. These tests use a variety of technologies, including enzyme-linked immunosorbent assays (ELISA), chemiluminescence, and polymerase chain reaction (PCR). Some of DiaSorin's most well-known tests include those for detecting HIV, hepatitis, and Lyme disease.
In addition to its diagnostic tests, DiaSorin also offers automated systems that streamline testing processes and improve efficiency in laboratories. The company is committed to innovation and invests heavily in research and development to continually improve and expand its product portfolio.
DiaSorin is committed to sustainability and ethical practices, with a specific focus on employee well-being, environmental impact, and social responsibility. The company also values diversity and inclusivity, with a workforce that represents over 25 different nationalities.
In 2020, DiaSorin's total revenue was over €870 million. The company continues to grow and expand its reach, with a strong commitment to improving healthcare worldwide.
The company's headquarters are located in Saluggia, Italy, and it also has major operations in the United States, China, and other European countries. DiaSorin's products are used in hospitals, laboratories, and research institutions worldwide.
The company's product line includes over 40 diagnostic test systems that are used to detect various diseases and conditions. These tests use a variety of technologies, including enzyme-linked immunosorbent assays (ELISA), chemiluminescence, and polymerase chain reaction (PCR). Some of DiaSorin's most well-known tests include those for detecting HIV, hepatitis, and Lyme disease.
In addition to its diagnostic tests, DiaSorin also offers automated systems that streamline testing processes and improve efficiency in laboratories. The company is committed to innovation and invests heavily in research and development to continually improve and expand its product portfolio.
DiaSorin is committed to sustainability and ethical practices, with a specific focus on employee well-being, environmental impact, and social responsibility. The company also values diversity and inclusivity, with a workforce that represents over 25 different nationalities.
In 2020, DiaSorin's total revenue was over €870 million. The company continues to grow and expand its reach, with a strong commitment to improving healthcare worldwide.
What is special about the company?
1. Pioneers in the field of immunodiagnostic technologies: DiaSorin was one of the first companies to develop and commercialize immunodiagnostic assays, which use antibodies and other components of the immune system to detect and measure various substances in the body. This has allowed them to be at the forefront of the diagnostic testing industry.
2. Global presence: DiaSorin has a strong global presence, with operations in more than 30 countries and a presence in all major markets, including North America, Europe, and Asia-Pacific. This enables them to reach a wide range of customers and offer innovative solutions to various healthcare challenges worldwide.
3. Extensive product portfolio: The company offers a wide range of diagnostic tests and systems for infectious diseases, autoimmune disorders, and endocrine and metabolic conditions. They have a diverse product portfolio, including automated and semi-automated analyzers, reagents, and software systems, which cater to the needs of various healthcare settings.
4. Focus on research and development (R&D): DiaSorin has a strong commitment to innovation and invests heavily in R&D. They have collaborations with leading academic and research institutions worldwide to develop new and more advanced diagnostic solutions.
5. Strong collaborations and partnerships: The company has established strong partnerships and collaborations with other healthcare companies, academic institutions, and government agencies. These alliances have helped them to bring cutting-edge diagnostic technologies and solutions to the market.
6. Quality and regulatory compliance: DiaSorin maintains a high level of quality and adheres to strict regulatory standards. They have ISO 13485 certification and follow Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).
7. Commitment to sustainability: DiaSorin is committed to sustainable development and implements environmentally responsible practices in its operations. They also focus on product design and manufacturing processes that reduce waste and energy consumption.
8. Social responsibility: The company has a strong sense of social responsibility and actively participates in various programs and initiatives to improve access to healthcare in underserved communities. They also support employee volunteerism and community service activities.
2. Global presence: DiaSorin has a strong global presence, with operations in more than 30 countries and a presence in all major markets, including North America, Europe, and Asia-Pacific. This enables them to reach a wide range of customers and offer innovative solutions to various healthcare challenges worldwide.
3. Extensive product portfolio: The company offers a wide range of diagnostic tests and systems for infectious diseases, autoimmune disorders, and endocrine and metabolic conditions. They have a diverse product portfolio, including automated and semi-automated analyzers, reagents, and software systems, which cater to the needs of various healthcare settings.
4. Focus on research and development (R&D): DiaSorin has a strong commitment to innovation and invests heavily in R&D. They have collaborations with leading academic and research institutions worldwide to develop new and more advanced diagnostic solutions.
5. Strong collaborations and partnerships: The company has established strong partnerships and collaborations with other healthcare companies, academic institutions, and government agencies. These alliances have helped them to bring cutting-edge diagnostic technologies and solutions to the market.
6. Quality and regulatory compliance: DiaSorin maintains a high level of quality and adheres to strict regulatory standards. They have ISO 13485 certification and follow Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).
7. Commitment to sustainability: DiaSorin is committed to sustainable development and implements environmentally responsible practices in its operations. They also focus on product design and manufacturing processes that reduce waste and energy consumption.
8. Social responsibility: The company has a strong sense of social responsibility and actively participates in various programs and initiatives to improve access to healthcare in underserved communities. They also support employee volunteerism and community service activities.
What the company's business model?
The DiaSorin company is a global leader in the development and production of innovative diagnostic solutions and testing systems for clinical laboratories. Their business model centers around providing high-quality, reliable and accurate diagnostic tools to healthcare professionals, enabling them to make informed decisions for patient care.
The company operates in two main segments: Molecular and Immunoassay. The Molecular segment focuses on detecting genetic material in patients' samples to diagnose various infectious diseases, including respiratory infections, sexually transmitted infections, and tuberculosis. The Immunoassay segment offers a wide range of diagnostic systems for immunodiagnostics, used in the detection of autoimmune diseases, endocrinology disorders, and tumor markers.
Their business model is based on a combination of proprietary technology, strong partnerships, and strategic investments in research and development. DiaSorin also collaborates with key opinion leaders, scientific associations, and healthcare institutions to validate and promote the effectiveness of their products.
Apart from selling diagnostic products, the company also provides training and support services to its customers, which include hospitals, private laboratories, and research centers. These services help customers to understand and effectively use the products, ensuring accurate and reliable results.
In terms of revenue, DiaSorin generates most of its sales from international markets, particularly Europe, the Asia Pacific, and North America. The company's customer base is diverse, ranging from large hospital laboratories to small private clinics.
In summary, the DiaSorin business model focuses on delivering high-quality diagnostics solutions through proprietary technology, partnerships, and research and development. The company's global presence, diverse customer base, and focus on customer support and training have contributed to its success as a leading player in the diagnostic industry.
The company operates in two main segments: Molecular and Immunoassay. The Molecular segment focuses on detecting genetic material in patients' samples to diagnose various infectious diseases, including respiratory infections, sexually transmitted infections, and tuberculosis. The Immunoassay segment offers a wide range of diagnostic systems for immunodiagnostics, used in the detection of autoimmune diseases, endocrinology disorders, and tumor markers.
Their business model is based on a combination of proprietary technology, strong partnerships, and strategic investments in research and development. DiaSorin also collaborates with key opinion leaders, scientific associations, and healthcare institutions to validate and promote the effectiveness of their products.
Apart from selling diagnostic products, the company also provides training and support services to its customers, which include hospitals, private laboratories, and research centers. These services help customers to understand and effectively use the products, ensuring accurate and reliable results.
In terms of revenue, DiaSorin generates most of its sales from international markets, particularly Europe, the Asia Pacific, and North America. The company's customer base is diverse, ranging from large hospital laboratories to small private clinics.
In summary, the DiaSorin business model focuses on delivering high-quality diagnostics solutions through proprietary technology, partnerships, and research and development. The company's global presence, diverse customer base, and focus on customer support and training have contributed to its success as a leading player in the diagnostic industry.
Interesting facts about the company
1. The company’s official name is DiaSorin S.p.A. and it was founded in 1968 in Saluggia, Italy.
2. DiaSorin specializes in the development, manufacture, and distribution of diagnostic tests for a variety of diseases and conditions.
3. The company’s initial focus was on developing diagnostic tests for thyroid and adrenal function. However, over the years it has expanded its portfolio to include tests for infectious diseases, cancer markers, and hormonal disorders.
4. DiaSorin was one of the first companies to develop an automated system for performing immunoassays, known as the LIAISON system. This system revolutionized the field of diagnostics by significantly reducing testing time and increasing accuracy.
5. In addition to its headquarters in Italy, DiaSorin has a strong presence in other countries, including the United States, Germany, France, United Kingdom, and China.
6. The company has a strong commitment to research and development, with over 15% of its revenue invested in this area. It has also established collaborations with renowned research institutions and universities around the world.
7. DiaSorin has been listed on the Italian Stock Exchange since 1999 and is currently a component of the FTSE MIB index.
8. In 2019, Diasorin was ranked among the top 100 healthcare companies in the world by Forbes.
9. The company’s mission is to improve people’s health and quality of life by providing innovative and reliable diagnostic solutions.
10. DaiSorin’s product portfolio includes over 1000 diagnostic tests, which are used in clinical laboratories and hospitals worldwide.
11. The company has won several awards for its innovative products and its commitment to sustainability and corporate social responsibility.
12. DiaSorin has a diverse and multicultural workforce, with employees from over 25 countries and speaking more than 30 languages.
13. The company’s logo, a red sparrow, symbolizes resilience, agility, and adaptability – qualities that are essential for a successful and sustainable business.
14. In addition to diagnostic tests, DiaSorin also offers training and support services to healthcare professionals to help them use its products effectively.
15. DiaSorin continues to grow and expand its product offerings through acquisitions and partnerships with other companies in the field of diagnostics and healthcare.
See Company Due Diligence:
2. DiaSorin specializes in the development, manufacture, and distribution of diagnostic tests for a variety of diseases and conditions.
3. The company’s initial focus was on developing diagnostic tests for thyroid and adrenal function. However, over the years it has expanded its portfolio to include tests for infectious diseases, cancer markers, and hormonal disorders.
4. DiaSorin was one of the first companies to develop an automated system for performing immunoassays, known as the LIAISON system. This system revolutionized the field of diagnostics by significantly reducing testing time and increasing accuracy.
5. In addition to its headquarters in Italy, DiaSorin has a strong presence in other countries, including the United States, Germany, France, United Kingdom, and China.
6. The company has a strong commitment to research and development, with over 15% of its revenue invested in this area. It has also established collaborations with renowned research institutions and universities around the world.
7. DiaSorin has been listed on the Italian Stock Exchange since 1999 and is currently a component of the FTSE MIB index.
8. In 2019, Diasorin was ranked among the top 100 healthcare companies in the world by Forbes.
9. The company’s mission is to improve people’s health and quality of life by providing innovative and reliable diagnostic solutions.
10. DaiSorin’s product portfolio includes over 1000 diagnostic tests, which are used in clinical laboratories and hospitals worldwide.
11. The company has won several awards for its innovative products and its commitment to sustainability and corporate social responsibility.
12. DiaSorin has a diverse and multicultural workforce, with employees from over 25 countries and speaking more than 30 languages.
13. The company’s logo, a red sparrow, symbolizes resilience, agility, and adaptability – qualities that are essential for a successful and sustainable business.
14. In addition to diagnostic tests, DiaSorin also offers training and support services to healthcare professionals to help them use its products effectively.
15. DiaSorin continues to grow and expand its product offerings through acquisitions and partnerships with other companies in the field of diagnostics and healthcare.
See Company Due Diligence:
Wait! There's more — sign up for free or log in